Wegovy's Country of Origin: Where the Medicine Actually Comes From

You've read a headline about fake pens, here's the supply chain reality

Say you've seen a news story about counterfeit weight-loss injections and you're now wondering whether the Wegovy you've been prescribed is genuinely what it claims to be. It's a reasonable thing to ask. Novo Nordisk produces semaglutide (the active ingredient in Wegovy) across its own manufacturing network. The primary sites are in Denmark, the company's home country, and in the United States. From those facilities, finished, quality-tested product moves into country-specific distribution channels. For the UK, that means a supply chain regulated by the MHRA, fulfilled by MHRA-licensed wholesalers, and dispensed only by pharmacies registered with the General Pharmaceutical Council.

The practical checking habit worth building: before you order from any online pharmacy, look it up on the GPhC pharmacy register. It takes under a minute. If the pharmacy isn't listed, walk away. That one step cuts through most of the noise around counterfeit product, because a GPhC-registered pharmacy is legally accountable for sourcing medicines through the licensed UK supply chain. The MHRA has warned publicly about fake pens (some containing insulin rather than semaglutide) seized from sellers operating outside that chain. Knowing the country of origin of the manufacturer is reassuring; knowing the pharmacy dispensing it is regulated is the more urgent check.

For context on the semaglutide molecule itself and how it became a licensed medicine, our page on where semaglutide comes from covers the research backstory in more detail.

Novo Nordisk, Denmark, and the MHRA licence: how the authorisation works for UK patients

Novo Nordisk was founded in Copenhagen in 1923, originally focused on insulin. Semaglutide (the molecule at the heart of Wegovy) emerged from its GLP-1 research programme decades later, modelled on a naturally occurring gut hormone called GLP-1. The company's global manufacturing footprint is large, but Denmark remains the centre of gravity: its flagship production sites at Kalundborg and elsewhere in the country have been significantly expanded in recent years to meet demand for GLP-1 medicines.

For UK patients, the country of manufacture is less legally relevant than the country of authorisation. The MHRA grants the UK marketing authorisation for Wegovy independently of the European Medicines Agency, a distinction that became explicit after the UK left the EU's regulatory framework. That means the product specifications, patient information leaflets, and approved dosing schedule for Wegovy in the UK are set by the MHRA, drawing on the clinical data submitted by Novo Nordisk. The MHRA's approval covers the product as manufactured and quality-tested at Novo Nordisk's licensed facilities, wherever those happen to be located.

If you're curious about how Wegovy got its name and how it differs from the diabetes version of the same molecule, the page on the origin of the Wegovy name explains that clearly. For the broader treatment picture, including eligibility and how a private prescription works in practice, our Wegovy overview is a good place to read next.

What this means if you're considering treatment in the UK

Knowing that Wegovy is manufactured by a well-established, audited pharmaceutical company is one piece of reassurance. The more practical question for anyone considering treatment is whether the route they're using to access it is legitimate. In the UK, Wegovy is a prescription-only medicine, which means it cannot legally be supplied without a prescription issued after a clinical assessment. That assessment exists for good reason: the NHS's patient information on semaglutide sets out the range of conditions and medicines that affect who the treatment is suitable for, and those are things a prescriber needs to weigh up before any supply.

Private clinics and online pharmacies operating legally in the UK source Wegovy through authorised UK wholesalers linked directly to Novo Nordisk's distribution. The pen you receive through a GPhC-registered pharmacy comes from the same manufacturing origin as hospital-dispensed stock. The concern isn't the factory, it's what happens between the factory and your front door when someone steps outside the licensed route. Sellers offering semaglutide without a clinical assessment, via social media or at prices that seem implausibly low, are operating outside that chain. The MHRA has raided UK sites producing counterfeit tirzepatide pens; the same risk applies to semaglutide.

If you're thinking about where to buy Wegovy safely, our page on how to access Wegovy in the UK walks through the options clearly. And if you'd like to understand the wider history of how semaglutide moved from a diabetes treatment to a licensed weight-management medicine, our page on what Wegovy was originally used for covers that journey, with more detail on the Wegovy original use research and regulatory background that shaped the medicine you're prescribed today.

At nume, our GPhC-registered pharmacy sources Wegovy through the licensed UK supply chain. Every order is reviewed by a prescriber (a real clinician, not a decision tree) before anything is dispensed. You can read about how our clinical team approaches that process on the clinical team page, and find answers to common questions on our FAQs page. If treatment sounds right for you, start your free consultation and a prescriber will assess your suitability the same day.